Recherches "plusieurs pathologies" CIRCA-HPV (IC 2017-01) Circulating Tumor DNA for the Early Detection of HPV-positive Pelvic Cancer Relapses. Paris, Saint-Cloud BRUNO BUECHER
Sein Adjuvant ASTEFANIA (WO42633 ) A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy Paris, Saint-Cloud
Recherches "plusieurs pathologies" REGOMUNE A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors Saint-Cloud SEGOLENE HESCOT
Recherches "plusieurs pathologies" SCANDARE (IC 2016-03) Prospective biobanking study in ovarian, breast and head and neck cancer patients aiming at better understand the link between the molecular alterations of the tumor itself, its microenvironment and immune response. Paris, Saint-Cloud CHRISTOPHE LE TOURNEAU
Recherches "plusieurs pathologies" ALCINA 2 Analysis of Circulating Tumor Markers in Blood Paris, Saint-Cloud FRANCOIS-CLEMENT BIDARD, FRANCOIS-CLEMENT BIDARD
Recherches "plusieurs pathologies" ALCINA-4 (IC 2020-11) Analysis of Circulating Tumor mArkers in Blood 4 - ALCINA 4 Paris, Saint-Cloud LUC CABEL, FRANCOIS-CLEMENT BIDARD
Recherches "plusieurs pathologies" ALCYTA (IC 2020-12) Exploration of Adaptive Antitumoral Immune Cells Through Leukapheresis in Cancer Patients: ALCYTA Paris, Saint-Cloud NICOLAS GIRARD, NICOLAS GIRARD
Gynécologie - Ovaires MK3475 B96 ENGOT ov65 A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTE-B96/ENGOT-ov65) Saint-Cloud
Sein SKYLINE Tiragolumab, atezolizumab and chemotherapy in triple negative breast cancer:;A phase II trial. Paris, Saint-Cloud FRANCOIS-CLEMENT BIDARD, FRANCOIS-CLEMENT BIDARD
Sein métastatique triple négatif TOPOLOGY A phase II study to evaluate the efficacy and toxicities;of PLX038, in patients with locally advanced or metastatic triple-negative breast cancer. Paris, Saint-Cloud FRANCOIS-CLEMENT BIDARD, FRANCOIS-CLEMENT BIDARD